Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMDNASDAQ:ALLKNASDAQ:GRCEOTCMKTS:MRMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$0.48+0.6%$0.53$0.40▼$1.18$7.47M2.14500,224 shs250,694 shsALLKAllakos$0.33$0.31$0.22▼$1.56$29.74M0.151.17 million shsN/AGRCEGrace Therapeutics$2.97$2.45$1.75▼$4.97$30.12M0.8958,111 shs12,561 shsMRMDMariMed$0.07-4.1%$0.09$0.07▼$0.29$28.77M3.15413,416 shs741,349 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos+0.64%-11.00%-12.00%-21.96%-50.62%ALLKAllakos0.00%0.00%+1.04%+15.07%-75.80%GRCEGrace Therapeutics0.00%+6.07%+29.13%-9.73%+296,999,900.00%MRMDMariMed-4.15%-7.27%-21.78%-45.19%-69.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMDAinos0.4894 of 5 stars0.04.00.00.00.60.80.6ALLKAllakos4.19 of 5 stars3.15.00.04.70.02.51.3GRCEGrace Therapeutics1.8461 of 5 stars3.50.00.00.01.10.81.3MRMDMariMed0.9559 of 5 stars0.05.00.00.01.70.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 0.00N/AN/AN/AALLKAllakos 2.20Hold$2.00507.72% UpsideGRCEGrace Therapeutics 3.00Buy$12.00304.04% UpsideMRMDMariMed 4.00Strong BuyN/AN/ACurrent Analyst Ratings BreakdownLatest AIMD, MRMD, ALLK, and GRCE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025GRCEGrace TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.004/3/2025MRMDMariMedNoble FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$106.21K70.33N/AN/A$5.23 per share0.09ALLKAllakosN/AN/AN/AN/A$1.93 per shareN/AGRCEGrace TherapeuticsN/AN/AN/AN/A$5.14 per shareN/AMRMDMariMed$148.60M0.19$0.01 per share5.59$0.19 per share0.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$13.77M-$1.29N/A∞N/AN/A-75.16%-50.22%8/4/2025 (Estimated)ALLKAllakos-$185.70M-$1.32N/AN/AN/AN/A-140.87%-86.22%8/6/2025 (Estimated)GRCEGrace Therapeutics-$12.85M-$1.16N/AN/AN/AN/A-20.10%-17.10%6/20/2025 (Estimated)MRMDMariMed-$16.03M-$0.03N/A∞N/A-10.97%-2.75%-1.06%8/6/2025 (Estimated)Latest AIMD, MRMD, ALLK, and GRCE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/20/2025Q4 2025GRCEGrace Therapeutics-$0.23N/AN/AN/AN/AN/A5/12/2025Q1 2025AIMDAinosN/A-$0.21N/A-$0.21N/A$0.11 million5/7/2025Q1 2025MRMDMariMed-$0.01-$0.01N/A-$0.01$38.33 million$37.96 million3/7/2025Q4 2024AIMDAinosN/A-$0.26N/A-$0.26N/AN/A3/5/2025Q4 2024MRMDMariMed-$0.01-$0.01N/A-$0.02$42.00 million$39.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/AALLKAllakosN/AN/AN/AN/AN/AGRCEGrace TherapeuticsN/AN/AN/AN/AN/AMRMDMariMedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos0.501.371.33ALLKAllakosN/A6.086.08GRCEGrace TherapeuticsN/A6.066.06MRMDMariMed1.011.550.73Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/AALLKAllakos84.64%GRCEGrace Therapeutics6.08%MRMDMariMed0.18%Insider OwnershipCompanyInsider OwnershipAIMDAinos10.39%ALLKAllakos16.12%GRCEGrace Therapeutics13.51%MRMDMariMed18.99%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos4015.43 million12.62 millionNot OptionableALLKAllakos19090.38 million74.94 millionOptionableGRCEGrace TherapeuticsN/A10.14 million8.77 millionN/AMRMDMariMed260388.71 million301.65 millionNot OptionableAIMD, MRMD, ALLK, and GRCE HeadlinesRecent News About These CompaniesNoble Financial Has Weak Outlook for MariMed FY2025 EarningsMay 15, 2025 | americanbankingnews.comWhat is Noble Financial's Forecast for MariMed Q2 Earnings?May 15, 2025 | americanbankingnews.comMariMed Inc.: MariMed Reports First Quarter 2025 EarningsMay 8, 2025 | finanznachrichten.deMariMed Inc. (MRMD) Reports Q1 Loss, Lags Revenue EstimatesMay 7, 2025 | zacks.comMariMed Reports First Quarter 2025 EarningsMay 7, 2025 | globenewswire.comMariMed Announces First Quarter 2025 Earnings DateApril 8, 2025 | globenewswire.comMariMed Promotes Ryan Crandall to Chief Commercial OfficerApril 7, 2025 | globenewswire.comMariMed's Betty's Eddies Expands Top-Selling Brand With Introduction of THC & CBG-Infused Caramel ChewsApril 3, 2025 | globenewswire.comMarimed launches Nature’s Heritage Flower in IllinoisApril 1, 2025 | markets.businessinsider.comMariMed Launches Nature's Heritage™ Flower in IllinoisApril 1, 2025 | globenewswire.comMariMed Inc. (PNK:MRMD) Q4 2024 Earnings Call TranscriptMarch 10, 2025 | msn.comMariMed Reports Record Revenue Amid Strategic GrowthMarch 6, 2025 | tipranks.comMariMed has price target chopped at VentumMarch 6, 2025 | cantechletter.comMariMed Inc. (MRMD) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | seekingalpha.comMariMed Reports Fourth Quarter and Full Year 2024 EarningsMarch 5, 2025 | globenewswire.comMariMed Completes Acquisition of First State Compassion, Strengthening Market Position in DelawareMarch 3, 2025 | globenewswire.comMariMed Announces Fourth Quarter and Full Year 2024 Earnings DateFebruary 11, 2025 | globenewswire.comMariMed Commences Wholesale Operations in MissouriDecember 23, 2024 | globenewswire.comMariMed Reports Third Quarter 2024 EarningsNovember 6, 2024 | globenewswire.comInHouse by MariMed Launches Help on the Homefront, to Support Veterans Facing Housing ChallengesOctober 31, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAIMD, MRMD, ALLK, and GRCE Company DescriptionsAinos NASDAQ:AIMD$0.48 +0.00 (+0.64%) As of 05/23/2025 04:00 PM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.Allakos NASDAQ:ALLK$0.33 0.00 (0.00%) As of 05/15/2025Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.Grace Therapeutics NASDAQ:GRCE$2.97 0.00 (0.00%) As of 05/23/2025 03:48 PM EasternGrace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.MariMed OTCMKTS:MRMD$0.07 0.00 (-4.15%) As of 05/23/2025 03:56 PM EasternMariMed Inc. engages in cultivation, production, and dispensing of medicinal and recreational cannabis in the United States and internationally. The company sells flowers and concentrates under the Nature's Heritage brand; and soft and chewy baked goods and a hot chocolate mix under Bubby's Baked brand; and drink mix under Vibations brand. It also offers chewable cannabis-infused mint tablet under the brand Kalm Fusion; and flower, vapes, and edibles under InHouse brand. In addition, the company provides supplement, nutrient-infused fruit chews under Betty's Eddies brand and ice creams under Emack & Bolio's brand. The company licenses its brands. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
